Metabolic Adaptation in Heart Failure and the Role of Ketone Bodies as Biomarkers

被引:0
|
作者
Foster, Michael W. [1 ]
Riley, Joshua M. [1 ]
Kaki, Praneet C. [2 ]
Al Soueidy, Amine [3 ]
Aligholiazadeh, Ehson [3 ]
Rame, J. Eduardo [1 ]
机构
[1] Thomas Jefferson Univ Hosp, Dept Med, Div Cardiol, 833 Chestnut St,Suite 600, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA
[3] Copper Univ Hosp, Dept Med, Camden, NJ USA
关键词
Heart failure; Cardiomyopathy; Biomarkers; Ketone bodies; Myocardial metabolism; BODY METABOLISM; LOW-CARBOHYDRATE; FAILING HEART; ASSOCIATION; CONTRACTILE; MORTALITY; DECLINE; DIET;
D O I
10.1007/s11897-024-00678-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of ReviewThe development and progression of heart failure is characterized by metabolic and physiologic adaptations allowing patients to cope with cardiac insufficiency. This review explores the changes in metabolism in heart failure and the potential role of biomarkers, particularly ketone bodies, in staging and prognosticating heart failure progression.Recent FindingsRecent insights into myocardial metabolism shed light on the heart's response to stress, highlighting the shift towards reliance on ketone bodies as an alternative fuel source. Elevated blood ketone levels have been shown to correlate with the severity of cardiac dysfunction, emphasizing their potential as prognostic indicators. Furthermore, studies exploring therapeutic interventions targeting specific metabolic pathways offer promise for improving outcomes in heart failure.SummaryKetones have prognostic utility in heart failure, and potentially, an avenue for therapeutic intervention. Challenges remain in deciphering the optimal balance between metabolic support and exacerbating cardiac remodeling. Future research endeavors must address these complexities to advance personalized approaches in managing heart failure.
引用
收藏
页码:498 / 503
页数:6
相关论文
共 50 条
  • [41] The effect of empagliflozin on ketone bodies in patients with heart failure with reduced ejection fraction (Empire HF)
    Larsen, J. H.
    Jensen, J.
    Andersen, C. F.
    Hoejlund, K.
    Kistorp, C. M.
    Poulsen, M. I.
    Tuxen, C.
    Gustafsson, F.
    Koeber, L.
    Schou, M.
    Moeller, J. E.
    Omar, M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [42] Effect of SGLT2 inhibition on ketone bodies in patients with stable chronic heart failure
    Pietschner, R.
    Kolwelter, J.
    Bosch, A.
    Kannenkeril, D.
    Ott, C.
    Schiffer, M.
    Achenbach, S.
    Schmieder, R. E.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 107 - 107
  • [43] Serum metabolic characteristics and biomarkers of early-stage heart failure
    Guo, Siqi
    Kong, Jing
    Zhou, Danya
    Lai, Minchao
    Chen, Yirun
    Xie, Dezhi
    Wang, Xiaobin
    Wang, Dian
    BIOMARKERS IN MEDICINE, 2020, 14 (02) : 119 - 130
  • [44] Metabolic and Signaling Roles of Ketone Bodies in Health and Disease
    Puchalska, Patrycja
    Crawford, Peter A.
    ANNUAL REVIEW OF NUTRITION, VOL 41, 2021, 2021, 41 : 49 - 77
  • [45] Suggested involvement of ketone bodies in the pathogenesis of the metabolic syndrome
    Alexandre, Adolfo
    MEDICAL HYPOTHESES, 2013, 80 (05) : 578 - 581
  • [46] METABOLIC TROUBLES OF KETONE-BODIES IN DOMESTIC MAMMALS
    MICHAUX, JM
    FONDEUR, S
    ROMDANE, MN
    MOUTHON, G
    RECUEIL DE MEDECINE VETERINAIRE, 1981, 157 (06) : 471 - 478
  • [47] Prognostic Role of Metabolic Exercise Testing in Heart Failure
    Agdamag, Arianne Clare
    Van Iterson, Erik H. H.
    Tang, W. H. Wilson
    Finet, J. Emanuel
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (13)
  • [48] Role of microRNA in metabolic shift during heart failure
    Pinti, Mark V.
    Hathaway, Quincy A.
    Hollander, John M.
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2017, 312 (01): : H33 - H45
  • [50] Biomarkers in heart failure
    Chen, Wei-Chung
    Tran, Kimberly D.
    Maisel, Alan S.
    HEART, 2010, 96 (04) : 314 - 320